INNOGEN-B (02591) Rises Nearly 7% Again, Surges Over 50% in Four Sessions as It Joins Hang Seng Composite Index

Stock News11-27

INNOGEN-B (02591) climbed nearly 7% again, marking a cumulative surge of over 50% in four trading sessions. At the time of writing, the stock was up 6.79% to HK$44.68, with a turnover of HK$35.37 million.

The rally follows the announcement of the Hang Seng Index Series quarterly review results on November 21, which confirmed INNOGEN-B's inclusion in the Hang Seng Composite Index. The changes will take effect on December 8, 2025. Analysts at CICC predict that INNOGEN-B meets the eligibility criteria for inclusion in the Stock Connect program.

INNOGEN-B is a biopharmaceutical company specializing in metabolic diseases, with a pipeline of innovative drugs targeting diabetes, obesity, and non-alcoholic steatohepatitis (NASH). All its drug candidates are independently developed with global intellectual property rights, supporting a worldwide R&D and market strategy.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1176759612?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-27 12:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1176759612","market":"fut","top_or_hot":-1,"title":"INNOGEN-B (02591) Rises Nearly 7% Again, Surges Over 50% in Four Sessions as It Joins Hang Seng Composite Index","media":"Stock News","content":"<p>INNOGEN-B (02591) climbed nearly 7% again, marking a cumulative surge of over 50% in four trading sessions. At the time of writing, the stock was up 6.79% to HK$44.68, with a turnover of HK$35.37 million.</p>\n<p>The rally follows the announcement of the Hang Seng Index Series quarterly review results on November 21, which confirmed INNOGEN-B's inclusion in the Hang Seng Composite Index. The changes will take effect on December 8, 2025. Analysts at CICC predict that INNOGEN-B meets the eligibility criteria for inclusion in the Stock Connect program.</p>\n<p>INNOGEN-B is a biopharmaceutical company specializing in metabolic diseases, with a pipeline of innovative drugs targeting diabetes, obesity, and non-alcoholic steatohepatitis (NASH). All its drug candidates are independently developed with global intellectual property rights, supporting a worldwide R&D and market strategy.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>INNOGEN-B (02591) Rises Nearly 7% Again, Surges Over 50% in Four Sessions as It Joins Hang Seng Composite Index</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nINNOGEN-B (02591) Rises Nearly 7% Again, Surges Over 50% in Four Sessions as It Joins Hang Seng Composite Index\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-27 12:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>INNOGEN-B (02591) climbed nearly 7% again, marking a cumulative surge of over 50% in four trading sessions. At the time of writing, the stock was up 6.79% to HK$44.68, with a turnover of HK$35.37 million.</p>\n<p>The rally follows the announcement of the Hang Seng Index Series quarterly review results on November 21, which confirmed INNOGEN-B's inclusion in the Hang Seng Composite Index. The changes will take effect on December 8, 2025. Analysts at CICC predict that INNOGEN-B meets the eligibility criteria for inclusion in the Stock Connect program.</p>\n<p>INNOGEN-B is a biopharmaceutical company specializing in metabolic diseases, with a pipeline of innovative drugs targeting diabetes, obesity, and non-alcoholic steatohepatitis (NASH). All its drug candidates are independently developed with global intellectual property rights, supporting a worldwide R&D and market strategy.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HSCI","symbol_name":"恒生综合指数","start_time":0,"source_url":"","article_id":"1176759612","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1176759612","pubTimestamp":1764216018,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"INNOGEN-B (02591) climbed nearly 7% again, marking a cumulative surge of over 50% in four trading sessions. At the time of writing, the stock was up 6.79% to HK$44.68, with a turnover of HK$35.37...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HSCI":"恒生综合指数","BK1161":"生物科技","02591":"银诺医药－Ｂ"},"translate_title":"英诺健-B(02591)再涨近7%四个交易日暴涨超50%加入恒生综指","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HSCI":1,"02591":1},"content_text":"INNOGEN-B (02591) climbed nearly 7% again, marking a cumulative surge of over 50% in four trading sessions. At the time of writing, the stock was up 6.79% to HK$44.68, with a turnover of HK$35.37 million.\nThe rally follows the announcement of the Hang Seng Index Series quarterly review results on November 21, which confirmed INNOGEN-B's inclusion in the Hang Seng Composite Index. The changes will take effect on December 8, 2025. Analysts at CICC predict that INNOGEN-B meets the eligibility criteria for inclusion in the Stock Connect program.\nINNOGEN-B is a biopharmaceutical company specializing in metabolic diseases, with a pipeline of innovative drugs targeting diabetes, obesity, and non-alcoholic steatohepatitis (NASH). All its drug candidates are independently developed with global intellectual property rights, supporting a worldwide R&D and market strategy.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1176759612","isCrawlerRequest":true}